Clinical trials: Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of…
- Trial name
- NCT04477343
- Testing
- SX-682, Nivolumab Injectable Product
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
Pancreatic Cancer
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.
- Trial name
- ViP (NCT01601808)
- Testing
- Caprelsa (vandetanib)
- Where
- 14 sites in United Kingdom
- Volunteers
- 142 people
- Sponsor
- University of Liverpool
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Pancreatic Neuroendocrine Tumors
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
This study is a multi-center, prospective, non-interventional (NI) study evaluating the safety and efficacy of sunitinib in Chinese patients with progressive, unresectable, advanced or metastatic well-differentiated, pancreatic…
- Trial name
- NCT02282059
- Testing
- sunitinib
- Where
- 24 sites in China
- Volunteers
- 100 people
- Sponsor
- Pfizer
Pancreas Cancer, Metastatic Pancreatic Cancer
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
This is a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy in patients with…
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
- Trial name
- NCT04605913
- Testing
- Modified GCN+TTF treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Pancreatic Cancer, Metastatic Adenocarcinoma
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
The objective of this research is to find out what effects (good and bad), the combination of gemcitabine and nab-paclitaxel therapy (GEM-ABR for the rest of the document), standard chemotherapy for pancreatic cancer, and the…
- Trial name
- NCT05776524
- Testing
- Nab paclitaxel, Gemcitabine, TheraBionic
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- THERABIONIC INC.
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Solid Tumor, Adult, Solid Tumor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- EVEREST-1 (NCT05736731)
- Testing
- A2B530, xT-Onco with HLA-LOH Assay
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- A2 Biotherapeutics Inc.
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back (recurrent) and have spread to another place in the body (metastatic) or…
- Conditions
- Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma
- Trial name
- NCT02159989
- Testing
- Sapanisertib, Ziv-Aflibercept
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004190
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- 19 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreas Cancer, Metastatic Pancreatic Cancer
FOLFIRINOX + NIS793 in Pancreatic Cancer
This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and…
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT05417386
- Testing
- FOLFIRINOX, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Colin D. Weekes, M.D., PhD
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine…
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00027638
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine
This will be a Phase II, multicenter, randomized, double blind, placebo controlled, study of six 28-day treatment cycles for patients with locally advanced, unresectable, or metastatic pancreatic cancer.
- Trial name
- RP101 (NCT00550004)
- Testing
- RP101, Gemcitabine (1000 mg/m2)
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 153 people
- Sponsor
- SciClone Pharmaceuticals
Adebrelimab (SHR-1316), Decitabine
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
Pancreatic cancer is a kind of digestive system tumor with extremely high malignancy and poor prognosis. Although the trend of benefit from immunotherapy in combination with chemotherapy is currently reflected in several…
- Conditions
- Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer
- Trial name
- NCT06454448
- Testing
- Adebrelimab;decitabine;
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreas Cancer, Metastatic
Electroporation Potentiated Immunotherapy in Cancer
The study is investigating the efficacy and safety of combined irreversible electroporation (IRE) and checkpoint inhibition in metastatic pancreatic cancer.
- Trial name
- EPIC-1 (NCT04835402)
- Testing
- Pembrolizumab, Irreversible electroporation
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Metastatic Pancreatic Adenocarcinoma
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
The question being asked in this study is: Will patients with advanced pancreatic cancer live significantly longer if they are treated with a combination of Gemcitabine and ON 01910.Na than if they are treated with Gemcitabine…
- Trial name
- ONTRAC (NCT01360853)
- Testing
- ON 01910.Na, Gemcitabine
- Where
- 46 sites in United States, Hungary and 3 more
- Volunteers
- 160 people
- Sponsor
- Traws Pharma, Inc.
Metastatic Pancreatic Cancer
Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma.
Retrospective, multicenter study including pts with metastatic pancreatic cancer who started first-line treatment with napaclitaxel plus Gemcitabine between December 2013 and June 2015 according to the routine practice.
- Trial name
- ANICE-PaC (NCT03620461)
- Testing
- Gemcitabine - nabpaclitaxel
- Volunteers
- 210 people
- Sponsor
- Galician Research Group on Digestive Tumors
Pancreatic Cancer
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether nitrocamptothecin is more effective than gemcitabine for pancreatic cancer.
- Trial name
- NCT00005869
- Testing
- gemcitabine hydrochloride, rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Tumors, Neoplasm Metastasis
Rapamycin With Grapefruit Juice for Advanced Malignancies
The purpose of this study is to determine the highest safe dose of rapamycin when given with a fixed amount of grapefruit juice.
- Trial name
- NCT00375245
- Testing
- Rapamycin (sirolimus), Grapefruit Juice
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Chicago
Pancreatic Cancer
Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
The goal of this clinical research study is to learn about symptoms related to chemotherapy and the disease, in patients with advanced pancreatic cancer.
- Trial name
- NCT00805688
- Testing
- Questionnaires, Blood Draws, Pedometer
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center